UroGen Cash And Short Term Investments from 2010 to 2024
| URGN Stock | USD 12.66 0.18 1.44% |
Cash And Short Term Investments | First Reported 2014-12-31 | Previous Quarter 241.9 M | Current Value 249.6 M | Quarterly Volatility 65 M |
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 966.1 K, Interest Expense of 15.5 M or Selling General Administrative of 94.9 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
UroGen | Cash And Short Term Investments |
Latest UroGen Pharma's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of UroGen Pharma over the last few years. Short Term Investments is an account in the current assets section of UroGen Pharma balance sheet. This account contains UroGen Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by UroGen Pharma fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. UroGen Pharma's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
UroGen Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 59,149,033 | |
| Geometric Mean | 25,692,055 | |
| Coefficient Of Variation | 89.88 | |
| Mean Deviation | 47,825,098 | |
| Median | 73,000,000 | |
| Standard Deviation | 53,162,688 | |
| Sample Variance | 2826.3T | |
| Range | 144M | |
| R-Value | 0.84 | |
| Mean Square Error | 872.6T | |
| R-Squared | 0.71 | |
| Significance | 0.000075 | |
| Slope | 10,039,838 | |
| Total Sum of Squares | 39567.8T |
UroGen Cash And Short Term Investments History
About UroGen Pharma Financial Statements
UroGen Pharma investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 137 M | 79.8 M |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with UroGen Stock
| 0.78 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against UroGen Stock
| 0.74 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.67 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.42 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.39 | PHVS | Pharvaris BV | PairCorr |
| 0.35 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of UroGen Pharma Correlation against competitors. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.